Leqembi for early Alzheimer’s, Skyclarys for Friedreich’s ataxia and Zurzuvae for postpartum depression meet or exceed Biogen’s internal sales expectations.

With blockbuster biosimilars under its belt, Samsung Bioepis marked triple-digit revenue growth in Q2, giving its parent company Samsung Biologics something to be proud of.

Concerns over the impact of the proposed US BIOSECURE Act on the CRO and CDMO segments linger despite proponent Mike Gallagher’s plan to leave Congress soon. Which global manufacturers could gain, what determines a shift away from Chinese companies and how imminent is this? Scrip brings insights from industry feedback and other sources.

In a tough R&D environment, delivery technology-based new drug development activities by Korean firms are poised to remain robust in 2024.